公开(公告)号：US20240342151A1

公开(公告)日：2024-10-17

申请号：US18582046

申请日：2024-02-20

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu

IPC: A61K31/454

CPC classification number: A61K31/454

Abstract: The compounds of the current disclosure include propynyl substituted indoles, where one or more hydrido radicals is substituted with a deuterium atom, wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant p53 protein.

公开(公告)号：US11938124B2

公开(公告)日：2024-03-26

申请号：US17348490

申请日：2021-06-15

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Arnold Levine ,  Melissa Dumble

IPC: A61K31/454 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/454 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/3955 ,  A61P35/00

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes methods of recovering wild-type function to p53 mutants by treating a cancer with a compound and a second agent. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used in combination with a secondary agent to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US11814373B2

公开(公告)日：2023-11-14

申请号：US17028720

申请日：2020-09-22

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Hongju Li ,  Bruce Fahr ,  Andrew Good

IPC: C07D405/14 ,  C07D209/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D491/107 ,  C07F7/08 ,  C07H15/26

CPC classification number: C07D405/14 ,  C07D209/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D491/107 ,  C07F7/0812 ,  C07H15/26

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US20210405056A1

公开(公告)日：2021-12-30

申请号：US17354071

申请日：2021-06-22

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Arnold LEVINE ,  Jonathan OLINER ,  Thomas W. DAVIS ,  Mary Kate McBRAYER

IPC: G01N33/574

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The methods described herein can detect and quantify the ability of a therapeutic agent to reconform a mutant conformation of mutant p53 to a conformation that possesses physiological activity of wild type p53. The disclosed method can be used as a companion diagnostic to detect and quantify the efficacy of a therapeutic agent in reducing the progression of cancers that contain a p53 mutation.

公开(公告)号：US20240269126A1

公开(公告)日：2024-08-15

申请号：US18421550

申请日：2024-01-24

Applicant: PMV PHARMACEUTICALS, INC.

Inventor： Arnold Levine ,  Melissa Dumble

IPC: A61K31/454 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/454 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/3955 ,  A61P35/00

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes methods of recovering wild-type function to p53 mutants by treating a cancer with a compound and a second agent. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used in combination with a secondary agent to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US11926632B2

公开(公告)日：2024-03-12

申请号：US17353199

申请日：2021-06-21

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Hongju Li ,  Bruce Fahr ,  Yi Chen

IPC: C07D487/10 ,  C07C237/40 ,  C07D213/36 ,  C07D213/38 ,  C07D213/73 ,  C07D213/81 ,  C07D215/12 ,  C07D231/56 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08 ,  C07D491/107

CPC classification number: C07D487/10 ,  C07C237/40 ,  C07D213/36 ,  C07D213/38 ,  C07D213/73 ,  C07D213/81 ,  C07D215/12 ,  C07D231/56 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08 ,  C07D491/107

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US20230046427A1

公开(公告)日：2023-02-16

申请号：US17353199

申请日：2021-06-21

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Hongju Li ,  Bruce Fahr ,  Yi Chen

IPC: C07D487/10 ,  C07D213/36 ,  C07D401/12 ,  C07D213/73 ,  C07D231/56 ,  C07C237/40 ,  C07D239/42 ,  C07D405/12 ,  C07D213/81 ,  C07D417/12 ,  C07D413/12 ,  C07D487/08 ,  C07D491/107

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US20230002403A1

公开(公告)日：2023-01-05

申请号：US17317423

申请日：2021-05-11

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Hongju Li ,  Bruce Fahr ,  Andrew Good

IPC: C07D491/107 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D498/18

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US20220315564A1

公开(公告)日：2022-10-06

申请号：US17028720

申请日：2020-09-22

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh VU ,  Romyr DOMINIQUE ,  Hongju LI ,  Bruce FAHR ,  Andrew GOOD

IPC: C07D405/14 ,  C07D401/12 ,  C07D209/14 ,  C07D405/12 ,  C07D401/14 ,  C07D403/06 ,  C07D409/12 ,  C07H15/26 ,  C07D471/04 ,  C07D409/14 ,  C07F7/08 ,  C07D491/107 ,  C07D471/08 ,  C07D403/12 ,  C07D417/14

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US20190119249A1

公开(公告)日：2019-04-25

申请号：US16163829

申请日：2018-10-18

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Hongju Li

IPC: C07D401/12 ,  C07D471/10 ,  C07D405/14 ,  C07D401/14 ,  C07D405/12 ,  C07D209/14 ,  C07D409/12 ,  C07D409/14 ,  C07D471/04 ,  C07D491/107

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.